CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Monte Rosa Therapeutics Plans Phase 2 Gout Trial of MRT-8102 in Q4 2026

By Public Technologies
  • Monte Rosa Therapeutics expects to start GEMINI-1, a Phase 2 trial of MRT-8102 in gout patients, in the fourth quarter of 2026.
  • The trial will evaluate prevention of recurrent flares following acute treatment, with initial data expected in the second half of 2027.
  • Preclinical results showed reduced joint swelling in rabbits with gouty arthritis and suppressed inflammatory activity in human experimental systems.
  • These findings will be presented at ACR Convergence on November 9, 2026, supporting the planned clinical evaluation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090700PRIMZONEFULLFEED9872774) on November 09, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk